NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: PharmaJet, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine - As part of the National Institute of Health, NIAID has awarded the contract to Inviragen and PharmaJet to advance the development of a needle-free, easy to administer vaccine, which will save millions from the debilitating dengue fever
Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine

 

NewswireToday - /newswire/ - Fort Collins, CO, United States, 2010/10/11 - As part of the National Institute of Health, NIAID has awarded the contract to Inviragen and PharmaJet to advance the development of a needle-free, easy to administer vaccine, which will save millions from the debilitating dengue fever.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen’s tetravalent dengue vaccine, DENVax™ delivered with PharmaJet’s convenient needle-free injection device.

“This NIAID contract will allow Inviragen and PharmaJet to continue our pioneering development of a needleless dengue vaccine,” commented Dr. Dan Stinchcomb, Inviragen’s Chief Executive Officer. “The PharmaJet injector has many properties that make it ideal for administering a dengue vaccine worldwide, potentially saving lives in affected countries and reducing the spread of the disease to new regions.”

Over 3.5 billion people live in countries that have frequent dengue outbreaks. The four dengue viruses are spread amongst humans by mosquitoes and cause an estimated 30 - 50 million cases of debilitating dengue fever and 0.5 to 2 million cases of life-threatening dengue hemorrhagic fever every year. A recent dengue outbreak in Florida highlights the continuing global spread of the disease.

“People of all ages fear needles and safe disposal of needle waste is a constant problem for health care providers. A needle-free dengue vaccine would be welcomed by patients in endemic countries and by travelers worldwide and could protect them from this devastating disease,” said Dr. Linda McAllister, PharmaJet’s interim Chief Executive Officer. “In this collaboration, PharmaJet will develop ‘needle-free’ syringes compatible with our jet injection technology for pre-filling with Inviragen’s novel dengue vaccine.”

Inviragen’s DENVax vaccine, developed by researchers at the CDC’s Division of Vector-Borne Diseases, is based on an attenuated DEN-2 virus that generates long-lasting anti-dengue immune responses. CDC scientists engineered this clinically tested, weakened DEN-2 virus to express DEN-1, DEN-3 or DEN-4 structural genes. DENVax is a four-way mixture of the three engineered viruses and the original DEN-2 strain. Inviragen has completed preclinical testing, formulation, and manufacturing of DENVax. Phase 1 clinical safety testing of DENVax, delivered by traditional needle and syringe, began earlier this year. Other dengue vaccine technologies in clinical testing require multiple injections with long intervals between doses. The goal of the Inviragen/PharmaJet collaboration is to develop a needle-free dengue vaccine delivery platform that can rapidly induce neutralizing antibody response after one or two easily administered doses.

PharmaJet’s jet injector creates a fine stream of pressurized liquid that penetrates the skin, quickly and effectively delivering doses of medicines and vaccines into different tissues. Jet injection eliminates needles from the process of administering vaccines and eliminates the costs and dangers associated with sharp needle waste. PharmaJet’s technology is FDA-cleared for delivery into the muscle (intramuscular) and under the skin (subcutaneous). PharmaJet is developing jet injectors for delivery between the skin layers (intradermal). For some vaccines, intradermal delivery has the potential to reduce the amount of vaccine required, leading to cost savings and expanded coverage for vaccines in limited supply.

“In preliminary animal model studies, we used PharmaJet technology to deliver DENVax intradermally. The combination was safe, induced neutralizing antibodies to all four dengue serotypes and protected against dengue infection,” noted Dr. Jorge Osorio, Inviragen’s Chief Scientific Officer. “Our ongoing Phase 1 clinical trial is assessing the safety and immune responses after both subcutaneous and intradermal delivery of DENVax by needle. Under this NIAID contract, we aim to test DENVax delivery with the PharmaJet device in children and adults in South America and Southeast Asia, regions that are significantly impacted by dengue disease.”

About Inviragen, Inc.
Inviragen (inviragen.com) is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical research stages include a chikungunya vaccine, a low-cost human papilloma virus vaccine, vaccines to protect against new forms of influenza, a vaccine to protect against West Nile and a combination plague/smallpox vaccine for biodefense. Inviragen has offices in Colorado, Wisconsin and Singapore.

About PharmaJet, Inc.
PharmaJet, Inc. (pharmajet.com) is a privately held company located in Denver, Colorado, with offices and representatives also in San Francisco, California, Baltimore, Maryland, Chicago, Illinois, and Sao Paulo, Brazil. PharmaJet develops, manufactures and markets vaccine and drug delivery products based on its proprietary needle free jet injection technology. PharmaJet’s US FDA 510(k) clearance relates to its 0.5 ml volume syringe, cleared for use with any liquid medicine. This technology is also cleared for use in the EU (CE Mark) and Brazil. The company meets GMP and ISO compliant standards for sterile single use products: 10993, 11737, 11607, and 11137. It is compliant with the ISO Quality Management System of 13485:2003, and the Needle Free Worldwide Standard of ISO 21649:2006.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PharmaJet, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Regina Todd - PharmaJet.com 
410-209-2389 todd[.]pharmajet.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PharmaJet, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PharmaJet, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  The Franchise Group

Visit  Mokuyobi





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)